Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.91
$0.126.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.93% | -11.28% | -207.63% | 65.15% | -40.84% |
| Total Depreciation and Amortization | -0.25% | -5.43% | -1.16% | 2.03% | -4.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 287.05% | -125.67% | 94.63% | -68.26% | 137.30% |
| Change in Net Operating Assets | -1,121.98% | -147.13% | 124.73% | 50.40% | -505.11% |
| Cash from Operations | -66.84% | -60.22% | 7.64% | 59.01% | -186.71% |
| Capital Expenditure | -66.22% | 54.90% | -9.39% | 63.83% | -22.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -115.14% | -- | -- | -406.71% |
| Cash from Investing | 92.07% | -116.17% | 6,493.53% | 98.51% | -457.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -124.11% | 44.27% | -54.42% | 49.40% | 55.00% |
| Issuance of Common Stock | -99.91% | 7,168,200.00% | -91.67% | -92.59% | -18.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.69% | 15,389.58% | -64.09% | 33.28% | 61.30% |
| Foreign Exchange rate Adjustments | -165.36% | 499.58% | -385.16% | -13.49% | 133.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.96% | 457.79% | 258.01% | 79.87% | -1,958.37% |